← Back to Search

Soft Tissue Filler

HArmonyCa Injectable Gel for Midface Volume Loss

Phase 3
Waitlist Available
Research Sponsored by Allergan
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 25 months
Awards & highlights

Study Summary

This trial is being conducted to assess the safety and effectiveness of HArmonyCa Lidocaine Injectable Gel for mid face soft tissue augmentation.

Who is the study for?
Adults in good health seeking to enhance their midface volume can join this trial. They must be able to consent and follow study rules, with no recent botulinum toxin or filler treatments, no tendency for keloid scarring, and not currently participating in other studies. Those with certain facial procedures, tattoos that affect assessment, recent dental work or planned during the study are excluded.Check my eligibility
What is being tested?
The trial is testing HArmonyCa Lidocaine Injectable Gel as a dermal filler for midface augmentation. Participants will either receive the gel immediately or after a control period of 3 months. The treatment's effects are monitored over up to 25 months through medical assessments and questionnaires.See study design
What are the potential side effects?
Potential side effects may include reactions at the injection site such as redness, swelling, pain or bruising; allergic responses due to ingredients like lidocaine; and possibly more general symptoms like headache or nausea.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 25 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 25 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants with Adverse Events
Face
Secondary outcome measures
Change from baseline on overall score in FACE-Q Satisfaction with appearance specific questionnaire
Change from baseline on overall score in FACE-Q Satisfaction with cheeks specific questionnaire
Change from baseline on overall score in FACE-Q Satisfaction with lower face and jawline specific questionnaire
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: HArmonyCa Lidocaine Injectable GelExperimental Treatment1 Intervention
Participants will receive HArmonyCa Lidocaine Injectable Gel on Day 1 and followed for up to 25 months. Participants will have the opportunity to receive optional touch-up and optional repeat treatment of HArmonyCa Lidocaine injectable gel during the follow-up duration period.
Group II: Control GroupExperimental Treatment1 Intervention
Participants will be followed for 3 months. Participants can opt to receive HArmonyCa Lidocaine Injectable Gel after 3 months and followed for up to 25 months.

Find a Location

Who is running the clinical trial?

AllerganLead Sponsor
781 Previous Clinical Trials
276,398 Total Patients Enrolled
ALLERGAN INC.Study DirectorAllergan
75 Previous Clinical Trials
79,088 Total Patients Enrolled

Media Library

HArmonyCa Lidocaine Injectable Gel (Soft Tissue Filler) Clinical Trial Eligibility Overview. Trial Name: NCT05452070 — Phase 3
Midface Volume Loss Research Study Groups: HArmonyCa Lidocaine Injectable Gel, Control Group
Midface Volume Loss Clinical Trial 2023: HArmonyCa Lidocaine Injectable Gel Highlights & Side Effects. Trial Name: NCT05452070 — Phase 3
HArmonyCa Lidocaine Injectable Gel (Soft Tissue Filler) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05452070 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does the use of HarmonyCa Lidocaine Injectable Gel carry any risks?

"There is both efficacy and safety data available for HArmonyCa Lidocaine Injectable Gel, so it received a score of 3."

Answered by AI

Does this research have a wide geographic scope?

"There are 8 clinical trial sites that are actively recruiting patients, including Humphrey Cosmetic Dermatology in Burlington, Pacific Derm in Woodbridge, and Skin Matters Medical Aesthetic Centre in Oakville."

Answered by AI

What is the aim of this research?

"The purpose of this study, which will last for 3 months, is to monitor the number of participants that experience adverse events. Additionally, the study will also track secondary outcomes like percentage of patients that see global aesthetic improvement on a 5-point scale and satisfaction with cheeks and lower face jawline pre and post treatment."

Answered by AI

Can new patients still join this investigation?

"That is accurate, the clinical trial in question is detailed on clinicaltrials.gov and is currently recruiting participants. The 160 potential subjects are needed from 8 different locations, with the original posting date being September 7th, 2022."

Answered by AI

How many people are in this trial?

"That is correct. The information available on clinicaltrials.gov confirms that this study, which was first posted on September 7th, 2020, is actively seeking patients. This particular trial is looking to recruit 160 patients from 8 different locations."

Answered by AI
~61 spots leftby Apr 2025